BLA 761108 · Alexion Pharm
Ultomiris
Ravulizumab-Cwvz · Injection · Complement Inhibitor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Dec 21, 2018
Approved uses
8
Original approval plus efficacy supplements
Registered trials
47
30 Phase 3, 15 recruiting
FAERS reports
14,195
8,138 serious, 1,058 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS MENINGOCOCCAL INFECTIONS ULTOMIRIS, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1) ] . Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early . Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ULTOMIRIS, unless the risks of delaying therapy with ULTOMIRIS outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional...
What it is approved for
From the label in effect Oct 29, 2026.
ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. ( 1.3 ) the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ( 1.4 ) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression ( 1.5 ). This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether ULTOMIRIS slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. 1.1 Paroxysmal Nocturnal Hemoglobinuria ULTOMIRIS is indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). 1.2 Atypical Hemolytic Uremic Syndrome ULTOMIRIS is indicated for the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E....
Mechanism: Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the membrane attack complex [MAC or C5b-9]) thus preventing MAC formation. ULTOMIRIS inhibits terminal complement-mediated intravascular hemolysis in patients with PNH and complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS. The precise mechanism by which ravulizumab-cwvz exerts its therapeutic effect in gMG patients is unknown, but is...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 21, 2026 Supplement 46 · Efficacy · priority review OrphanLetterLabelMedication Guide
- Mar 22, 2024 Supplement 26 · Efficacy OrphanLetterLabel
- Jul 22, 2022 Supplement 21 · Efficacy OrphanLabelLetter
- Apr 27, 2022 Supplement 23 · Efficacy · priority review LabelLetter
- Jun 7, 2021 Supplement 12 · Efficacy · priority review OrphanLetterLabel
- Oct 9, 2020 Supplement 5 · Efficacy OrphanLetterLabel
- Oct 18, 2019 Supplement 1 · Efficacy · priority review OrphanLabelLetterPediatric Other
- Dec 21, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- ULTOMIRIS · RAVULIZUMAB-CWVZ 300MG/30ML(10MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ravulizumab" as an intervention, any sponsor and status, largest first.
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Pivotal-lookingStatus unknown
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
NCT04390464 · 1,167 participants (planned) · Start May 8, 2020 · Primary completion May 7, 2021
Drug: Ravulizumab; Baricitinib · For: COVID19
Sites: Cambridge, United Kingdom
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06291376 · 584 participants · Start Mar 29, 2024 · Primary completion Jan 5, 2026
Drug: Ravulizumab; Placebo · For: Immunoglobulin A Nephropathy; IgAN
Sites: Alabaster, Alabama; Phoenix, Arizona; Los Angeles, California · 246 sites in all
- ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKEPivotal-lookingTerminated
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT05746559 · 555 participants · Start Apr 6, 2023 · Primary completion Oct 7, 2025
Drug: Placebo; Ravulizumab · For: Chronic Kidney Disease; CKD; Cardiac Disease and 1 more
Sites: Orange, California; San Francisco, California; Stanford, California · 130 sites in all
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDPivotal-lookingRecruiting
Massachusetts General HospitalAcademic, hospital or other
NCT07010302 · 540 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 2030
Drug: Rituximab (R); Eculizumab (Soliris®) and 3 more · For: NMOSD
Sites: Boston, Massachusetts; Berlin, Germany · 3 sites in all
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06830798 · 450 participants (planned) · Start May 19, 2025 · Primary completion Nov 30, 2027
Drug: Ravulizumab; Placebo · For: Delayed Graft Function; DGF; Kidney Transplant
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 130 sites in all
- An Efficacy and Safety Study of Ravulizumab in ALS ParticipantsPivotal-lookingTerminated
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT04248465 · 382 participants · Start Mar 30, 2020 · Primary completion Oct 17, 2021
Drug: Placebo; Ravulizumab · For: Amyotrophic Lateral Sclerosis; ALS
Sites: Phoenix, Arizona; Scottsdale, Arizona; Loma Linda, California · 95 sites in all
- ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)Pivotal-lookingCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT02946463 · 272 participants · Start Dec 12, 2016 · Primary completion Feb 28, 2023
Drug: Ravulizumab; Eculizumab · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Los Angeles, California; Whittier, California; Fort Worth, Texas · 120 sites in all
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05744921 · 202 participants (planned) · Start Mar 7, 2023 · Primary completion Oct 10, 2028
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Curitiba, Brazil; São Paulo, Brazil; Toronto, Canada · 50 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue1,819
- asthenia925
- drug ineffective775
- headache772
- death677
- off label use581
- dyspnoea548
- muscular weakness532
- myasthenia gravis511
- malaise483
- pain452
- haemoglobin decreased423
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2018 | 2 |
| 2019 | 599 |
| 2020 | 434 |
| 2021 | 433 |
| 2022 | 512 |
| 2023 | 2,079 |
| 2024 | 4,319 |
| 2025 | 3,090 |
| 2026 | 2,726 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ultomiris (Ravulizumab-Cwvz)
2024 spending
$233M
Beneficiaries
701
3,951 claims
Per beneficiary
$332,291
$2,110.49 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,577,129 |
| 2021 | $15,592,736 |
| 2022 | $46,988,003 |
| 2023 | $159,533,070 |
| 2024 | $232,936,291 |
Part B: Ultomiris (Ravulizumab-Cwvz) · HCPCS J1303
2024 spending
$609M
Beneficiaries
1,844
10,789 claims
Per beneficiary
$330,448
2024 ASP limit $221.37 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $146,656,849 |
| 2021 | $177,654,131 |
| 2022 | $263,257,392 |
| 2023 | $471,519,422 |
| 2024 | $609,346,340 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
Vu T, Meisel A, Mantegazza R, et al. · NEJM Evid 2022 · Randomized Controlled Trial, Multicenter Study
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. · Blood 2019 · Clinical Trial, Phase III, Comparative Study
- Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.
Kulasekararaj A, Brodsky R, Schrezenmeier H, et al. · Ann Hematol 2025 · Clinical Trial, Phase III, Multicenter Study
- The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, et al. · Kidney Int 2020 · Clinical Trial, Phase III
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG, Hill A, Rottinghaus ST, et al. · Blood 2019 · Clinical Trial, Phase III, Comparative Study
- Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
Meisel A, Annane D, Vu T, et al. · J Neurol 2023 · Clinical Trial, Phase III
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.